BRIDGEWATER, N.J.--(BUSINESS WIRE)--Dec. 15, 2005--Sapphire Therapeutics’ novel oral ghrelin mimetic, RC-1291, has demonstrated potent dose-dependent appetite-stimulating effects in Phase I study data presented at the 3rd Rome Cachexia Conference, December 8-10. RC-1291 is currently undergoing Phase II studies in patients with cancer-related anorexia/cachexia syndrome, a common, life-threatening complication of underlying malignancies.
